Saturday 17 October 2026
Export SNGX’s income statement to Excel — free account
Soligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.
0.35
0.01
−2.78%
Follow SNGX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
3 | 3 | 2 | 2 | 2 | 4 | 4 | 3 | — | — |
Altman Z-Score |
(18.80) | (21.80) | (22.21) | (32.63) | (14.45) | (10.41) | (24.28) | (33.86) | (38.90) | — |
P/S ratio |
0.79 | 2.53 | 2.16 | 6.07 | 14.92 | 32.13 | 21.78 | 7.86 | 9.06 | — |
Altman Z″-Score (non-manufacturers) |
(44.07) | (52.73) | (52.04) | (81.46) | (33.29) | (22.59) | (58.20) | (77.77) | (88.34) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(5.79) | (5.94) | (4.23) | (10.64) | (8.53) | (8.67) | (5.70) | (3.61) | (2.01) | — |
Beneish M-Score |
(1.84) | (2.46) | (2.93) | (3.34) | (5.21) | (3.00) | (2.93) | 0.17 | — | — |
P/B ratio |
1.12 | 2.18 | 1.80 | 19.30 | 9.41 | 2.47 | 0.00 | 2.62 | 1.09 | — |
Price to Tangible BV |
1.13 | 2.20 | 1.82 | 19.56 | 9.42 | 2.47 | 0.00 | 2.62 | 1.09 | — |
EV/Sales |
(0.05) | 1.10 | 0.45 | 4.93 | 11.36 | 12.62 | 18.38 | 1.68 | (1.93) | — |
EV/EBITDA |
0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | — |
EV/Operating CF |
0.11 | (0.91) | (0.32) | (3.04) | (2.34) | (0.89) | (1.38) | (0.16) | 0.11 | — |
EV/FCF |
0.11 | (0.91) | (0.32) | (3.03) | (2.34) | (0.89) | (1.38) | (0.16) | 0.11 | — |
Quick Ratio |
3.48 | 2.83 | 2.42 | 1.09 | 3.16 | 4.18 | 0.82 | 1.40 | 1.61 | 2.15 |
Current Ratio |
3.52 | 2.92 | 2.46 | 1.19 | 3.20 | 4.22 | 0.84 | 1.55 | 1.82 | 2.39 |
Net Debt/EBITDA |
1.56 | 1.04 | 1.00 | 0.50 | 0.45 | 1.23 | 0.23 | 0.68 | 0.68 | 0.67 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.64% | 51.67% | 37.08% | 70.95% | 33.28% | 15.31% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.09 | 2.75 | 0.93 | (4.10) | 1.29 | 0.33 | 0.00 |
Asset Turnover |
1.18 | 0.55 | 0.52 | 0.51 | 0.17 | 0.04 | 0.05 | 0.07 | 0.01 | 0.00 |
Operating CF/Net income |
1.54 | 0.91 | 0.81 | 0.80 | 0.65 | 0.94 | 0.92 | 1.40 | 1.02 | 0.93 |
Capex/Depreciation |
(0.07) | (0.38) | (0.02) | (0.45) | (0.11) | (0.16) | (0.20) | 0.00 | 0.00 | (1.84) |
Interest Coverage |
(2,595.27) | — | (56.97) | (70.74) | (1,705.18) | (14.48) | (17.31) | (156.78) | 44.11 | — |
| (87.96%) | (104.21%) | (141.27%) | (241.83%) | (680.47%) | (173.54%) | (334.43%) | (23,801.16%) | (248.98%) | (235.50%) | |
| (36.77%) | (72.13%) | (88.82%) | (102.43%) | (127.87%) | (53.68%) | (67.06%) | (51.01%) | (88.11%) | (121.75%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(44.64%) | (114.85%) | (144.70%) | (768.55%) | (131.91%) | (61.83%) | 521.64% | (182.37%) | (207.38%) | (214.80%) |
Average Days of Receivables |
42.16 | 90.24 | 83.68 | 115.33 | 87.39 | 107.47 | 84.36 | 84.84 | 0.00 | — |
Research and Development Expense of Revenue |
41.11% | 101.37% | 128.80% | 175.44% | 627.12% | 993.07% | 837.19% | 394.65% | 4,374.87% | 0.00% |
Selling, General and Administrative Expense of Revenue |
32.82% | 59.07% | 56.32% | 75.18% | 183.47% | 607.63% | 705.33% | 534.02% | 3,530.90% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.01% | 9.12% | 7.27% | 8.13% | 17.37% | 47.20% | 57.48% | 58.76% | 289.45% | 0.00% |
Graham Net Nets |
0.88 | 0.45 | 0.54 | 0.04 | 0.09 | 0.39 | (0.14) | 0.34 | 0.89 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.86 | 0.00 | 0.00 | — |
Earnings Yield |
(40.03%) | (52.05%) | (86.00%) | (33.78%) | (52.32%) | (46.95%) | (68.05%) | (105.88%) | (226.30%) | — |
Free Cash Flow Yield |
(60.50%) | (47.50%) | (63.94%) | (26.79%) | (32.56%) | (44.37%) | (61.27%) | (130.64%) | (187.79%) | — |
Revenue per Share |
720.61 | 212.21 | 95.47 | 57.30 | 20.59 | 4.93 | 5.29 | 1.73 | 0.07 | 0.00 |
Operating CF per Share |
(343.61) | (254.32) | (131.96) | (92.94) | (99.95) | (70.21) | (70.51) | (17.74) | (5.06) | (1.98) |
Capex per Share |
(0.50) | (1.03) | (0.02) | (0.31) | (0.06) | (0.07) | (0.07) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(344.11) | (255.35) | (131.98) | (93.25) | (100.01) | (70.28) | (70.58) | (17.74) | (5.06) | (1.98) |
Cash per Share |
605.01 | 305.06 | 163.64 | 67.09 | 162.97 | 155.77 | 74.47 | 17.41 | 4.71 | 1.53 |
Shareholders Equity per Share |
510.15 | 246.86 | 114.39 | 18.03 | 32.65 | 64.13 | (13.77) | 5.20 | 2.48 | 1.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
510.15 | 246.86 | 114.39 | 18.03 | 32.65 | 64.13 | (13.77) | 5.20 | 2.48 | 1.02 |
Free Cash Flow |
(4.99) | (6.54) | (7.25) | (7.53) | (11.46) | (11.75) | (12.66) | (8.60) | (8.40) | (10.27) |
Working Capital |
7.24 | 6.19 | 6.13 | 1.18 | 13.39 | 20.28 | (2.66) | 3.36 | 3.98 | 5.15 |
Capital Expenditures |
(0.01) | (0.03) | 0.00 | (0.02) | (0.01) | (0.01) | (0.01) | — | — | (0.01) |
Net Current Asset Value |
7.24 | 6.19 | 6.13 | 1.18 | 3.32 | 10.42 | (2.90) | 2.23 | 3.98 | 4.91 |
EV/EBIT |
0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.64 | 1.84 | 2.25 | 1.51 | 2.71 | 3.43 | 3.57 | 1.61 | 0.95 | 0.36 |
Cash ROIC |
(30.86%) | (46.27%) | (47.47%) | (107.56%) | (35.05%) | (25.15%) | (60.24%) | (60.47%) | (63.14%) | (77.66%) |
Accounts Receivable Turnover |
6.55 | 4.26 | 4.12 | 3.48 | 2.33 | 2.04 | 4.11 | 4.05 | 0.00 | — |
Accounts Payable Turnover |
3.68 | 2.49 | 2.37 | 1.47 | 0.75 | 0.29 | 0.16 | 0.30 | 0.13 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
73.92 | 148.50 | 168.79 | 279.87 | 426.92 | 1,465.56 | 2,561.76 | 546.61 | 2,041.74 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.60 | 1.27 | 1.27 | 1.33 | 1.01 | 0.40 | 0.23 | 0.21 | — | — |
Average Payables |
2.29 | 1.73 | 1.94 | 2.43 | 2.43 | 2.53 | 3.40 | 2.49 | 0.89 | 0.89 |
Average Assets |
8.83 | 9.91 | 10.02 | 9.13 | 13.83 | 23.38 | 20.57 | 12.04 | 9.38 | 9.10 |
Average Common Equity |
3.69 | 6.86 | 6.30 | 3.87 | 2.60 | 7.23 | 4.13 | 0.03 | 3.32 | 4.71 |
Columns are period end dates